Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy
Abstract Background Gastrointestinal involvement in Gaucher disease is very rare, and appears to be unresponsive to enzyme replacement therapy (ERT). Case presentation Here, we describe identical twin, splenectomized, non-neuronopathic Gaucher patients on long-term ERT for 9 years, who complained of...
Main Authors: | Yoo-Mi Kim, Dong Hoon Shin, Su Bum Park, Chong Kun Cheon, Han-Wook Yoo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-05-01
|
Series: | BMC Medical Genetics |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12881-017-0403-x |
Similar Items
-
Profile of eliglustat tartrate in the management of Gaucher disease
by: Sechi A, et al.
Published: (2016-01-01) -
The clinical efficacy of imiglucerase versus eliglustat in patients with Gaucher's disease Type 1: A systematic review
by: Azita Nabizadeh, et al.
Published: (2018-01-01) -
Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease
by: Nathaniel Kleytman, et al.
Published: (2021-12-01) -
Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
by: Jennifer Ibrahim, et al.
Published: (2016-09-01) -
Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain
by: Scott D. Larsen, et al.
Published: (2012-02-01)